Related by context. All words. (Click for frequent words.) 74 dose escalation trial 73 Phase 1b 73 Phase Ib 70 dose escalation study 70 Phase 2b study 70 Dose escalation 69 phase Ib 69 IIa trial 69 placebo controlled 68 dose cohorts 68 dose titration 68 Phase 2a trial 68 ascending dose 68 dose escalation Phase 68 Phase 2b trial 67 nonrandomized 67 dose regimens 67 phase IIb clinical 67 placebo controlled Phase 67 Phase Ib II 67 dose cohort 67 phase IIb 67 HGS ETR1 67 nab paclitaxel 66 dosing cohorts 66 Phase #b/#a 66 unblinded 66 dosage regimens 66 dosing cohort 66 Phase Ib study 66 CR# vcMMAE 66 multicenter Phase 65 randomized Phase 65 viral kinetic 65 randomized 65 phase IIa 65 Phase Ib clinical 65 oral ridaforolimus 65 carboplatin paclitaxel 65 imetelstat 65 Phase 1a 65 Phase IIb 65 evaluable patients 65 telaprevir dosing 65 blinded randomized 65 placebo controlled clinical 65 multiple ascending dose 65 mg/m2 dose 65 Bezielle 65 tolerated dose MTD 65 HGS# 64 double blinded placebo 64 vicriviroc 64 dose escalation clinical 64 multicenter randomized placebo controlled 64 noninferiority 64 DLTs 64 IMC A# 64 phase IIa clinical 64 Phase 1b trial 64 Panzem R NCD 64 maximally tolerated dose 64 APTIVUS r 64 multicenter Phase II 64 ascending doses 64 dose dose escalation 64 randomized Phase III 64 forodesine 64 pivotal Phase 64 Phase 2a 64 CA4P 64 sunitinib 64 obatoclax 64 PXD# 64 PSMA ADC 64 confirmatory Phase III 64 chemotherapy docetaxel 64 multicentre 64 BRIM2 64 mg kg dose 64 alvespimycin 64 ganetespib 64 clinical trial 64 eniluracil 64 axitinib 63 CIMZIA TM 63 anti leukemic 63 Maximum Tolerated Dose 63 Cloretazine R VNP#M 63 mapatumumab 63 tolerability 63 mcg kg 63 Phase IIb trials 63 dosing regimens 63 Phase 1b clinical 63 INCB# [001] 63 Phase IIb trial 63 randomized multicenter 63 tanespimycin 63 Phase III clinical 63 mCi kg 63 MGCD# [001] 63 HuMax EGFr 63 AP# [003] 63 CONSERV 63 pharmacokinetic 63 prospective randomized controlled 63 prospective multicenter 63 label dose escalation 63 dose limiting toxicities 63 controlled multicenter 63 mg dose 63 Phase IIa trial 63 ofatumumab 63 PF # [001] 63 enzastaurin 63 oral deforolimus 63 seliciclib 62 IMGN# 62 pivotal Phase III 62 pharmacodynamic PD 62 oral rivaroxaban 62 treatment naive genotype 62 Dacogen injection 62 Phase IIa 62 randomized controlled 62 Phase III 62 randomized placebo controlled 62 dosing 62 sapacitabine 62 elotuzumab 62 dosing schedules 62 chemoradiotherapy 62 Phase 2a clinical 62 active comparator 62 μg dose 62 DAPT 62 PREZISTA r 62 blind placebo 62 pertuzumab 62 heavily pretreated 62 vinorelbine 62 pharmacokinetic PK 62 HCV SPRINT 62 pomalidomide 62 blinded placebo controlled 62 Traficet EN 62 DSMB 62 lintuzumab 62 phase IIb trial 62 MGd 62 registrational 62 ENDEAVOR IV 62 Phase III trials 62 pharmacodynamics 62 randomized double 62 monotherapy 62 desvenlafaxine succinate 62 AQ4N 62 blinded randomized placebo controlled 62 MNTX 62 docetaxel Taxotere R 62 intermittent dosing 62 Phase 2b 62 administered subcutaneously 62 Phase Ia 61 limiting toxicity 61 CYT# 61 randomized Phase 2b 61 Phase III randomized 61 LUX Lung 61 gemcitabine 61 prospective randomized placebo 61 pharmacodynamic effects 61 tesmilifene 61 optimal dosing 61 Phase #/#a 61 HGS ETR2 61 decitabine 61 double blinded randomized 61 multicenter randomized double 61 dose escalation phase 61 EOquin TM 61 PEG Interferon lambda 61 multicenter randomized 61 masked placebo controlled 61 phase 2a 61 Phase 2b clinical 61 ongoing Phase 1b 61 posaconazole 61 brivaracetam 61 CoFactor 61 prospective randomized 61 metastatic RCC 61 APTIVUS 61 TORISEL 61 Phase IIb clinical 61 placebo controlled studies 61 deforolimus 61 randomized controlled Phase 61 randomized multicentre 61 AeroLEF TM 61 phase IIb study 61 mg/m2 cohort 61 TELCYTA 61 Phase IIIb clinical 61 subcutaneous SC 61 randomized Phase IIb 61 phase IIIb 61 Sym# 61 clinical pharmacology studies 61 randomized discontinuation trial 61 dosing interval 61 teriflunomide 61 BCIRG 61 perifosine 61 cisplatin vinorelbine 61 docetaxel 61 mg administered orally 61 CLORETAZINE TM VNP#M 61 crizotinib PF # 61 Allovectin 7 ® 61 insulin detemir 61 Xelox 61 Phase 2b randomized 61 LEVADEX 61 low dose cytarabine 61 blind randomized placebo 61 placebo controlled Phase III 61 randomized blinded 61 Phase III pivotal 61 APPRAISE 61 ZOLINZA 61 PRECiSE 61 vandetanib 61 bolus dose 60 mitoxantrone 60 randomized clinical 60 rindopepimut 60 imatinib therapy 60 double blind placebo 60 intravenous dosing 60 antitumor activity 60 HuMax CD4 60 adecatumumab 60 tapentadol ER 60 relapsed refractory multiple myeloma 60 nitazoxanide 60 glufosfamide 60 #mg/m# [001] 60 HCD# [002] 60 single ascending dose 60 glatiramer acetate 60 FOLFOX 60 rALLy clinical trial 60 iniparib BSI 60 Phase Ib clinical trials 60 Phase IIB 60 Phase III randomized controlled 60 multicentre randomized 60 docetaxel chemotherapy 60 abatacept 60 placebo controlled trials 60 placebo controlled randomized 60 PEG PAL 60 mg BID 60 rituximab 60 MERLIN TIMI 60 unblinding 60 prespecified 60 Fludara 60 RG# [001] 60 ISTODAX 60 Maximum Tolerated Dose MTD 60 telaprevir dosed 60 dose regimen 60 SUCCEED trial 60 motesanib 60 subgroup analyzes 60 FOLFIRI 60 mg/m2/day 60 chemoradiation 60 PRT# 60 patients evaluable 60 Azedra 60 Phase #b/#a trial 60 #mg/m# [002] 60 KRAS mutations occur 60 velafermin 60 EVEREST II 60 peg interferon 60 ADVANCE PD 60 COMFORT II 60 otelixizumab 60 Amrubicin 60 atazanavir ritonavir 60 cytotoxic chemotherapy 60 VNP#M 60 GRN#L 60 lesinurad 60 Pivotal Trial 60 rALLy trial 60 Neulasta ® 60 aflibercept 60 temsirolimus 60 rFVIIa 60 bicifadine 60 elacytarabine 59 timepoint 59 refractory CLL 59 AEGR 59 T DM1 59 torezolid phosphate 59 PEG SN# 59 antibody MAb 59 eculizumab 59 mg QD 59 adalimumab 59 custirsen 59 ZYBRESTAT 59 blind randomized 59 ELACYT 59 bendamustine 59 treatment naïve genotype 59 FOLPI 59 Fibrillex TM 59 LibiGel Phase III 59 non inferiority 59 intravitreal injection 59 platinum refractory 59 Randomized Phase 59 CRLX# 59 registrational trial 59 COPAXONE R 59 methylnaltrexone 59 sunitinib malate 59 neoadjuvant 59 HCV RESPOND 2 59 evaluable subjects 59 randomized #:#:# 59 multicenter 59 ancrod 59 bortezomib 59 virological failure 59 pharmacokinetic studies 59 Exherin TM 59 rt PA 59 resminostat 59 Amigal 59 XL# SAR# 59 EVIZON 59 BAY #-# 59 ATL# [001] 59 zalutumumab 59 viral kinetics 59 multicenter placebo controlled 59 bosentan 59 pharmacodynamic profile 59 Phase IIa trials 59 neurologic progression 59 LEXIVA r 59 heavily pretreated patients 59 temozolomide 59 PROMACTA 59 Phase II 59 relapsed MM 59 placebo controlled dose escalation 59 EFAPROXYN 59 pazopanib 59 4mg/kg 59 galiximab 59 elagolix 59 pharmacokinetics 59 Phase IIIb 59 Cotara 59 trabectedin 59 pharmacokinetic profile 59 oral methylnaltrexone 59 darunavir ritonavir 59 continuous intravenous infusion 59 MADIT II 59 Phase IIa clinical 59 REOLYSIN ® 59 phase Ib clinical 59 piperacillin tazobactam 59 safety tolerability pharmacokinetics 59 XL# [003] 59 valopicitabine 59 placebo controlled clinical trials 59 mg/m2 59 stage IIIB 59 q#h 59 label multicenter 59 cilengitide 59 SYMMETRY trial 59 adjuvant therapy 59 pharmacodynamic 59 brentuximab vedotin 59 vidofludimus 59 confirmatory clinical 59 belinostat 59 oral dosing 59 dirucotide 59 BRIM3 59 celgosivir 59 randomized multicenter Phase III 59 randomized multicenter trial 59 Cloretazine 59 Phase IIb clinical trials 59 randomized #:# 59 ILLUMINATE 59 tocilizumab 59 BEACOPP 59 HER2 positive metastatic breast 59 randomization 59 pharmacodynamics PD 59 dosing regimen 59 budesonide foam 58 tolvaptan 58 #mg dose [002] 58 FOLFOX4 58 PEARL SC 58 CHOP chemotherapy 58 Vicinium TM 58 ARIKACE 58 TAXUS VI 58 GAMMAGARD 58 palonosetron 58 peg IFN 58 infliximab 58 MIRCERA 58 nonclinical studies 58 mertansine 58 Blinatumomab 58 YONDELIS 58 Imprime PGG 58 PRECISE Trial 58 PRE SURGE 58 plasma uric acid 58 NP2 Enkephalin 58 comparator arm 58 OncoVEX GM CSF 58 titration 58 MAGE A3 ASCI 58 metastatic sarcomas 58 dacarbazine 58 rapid virologic response 58 LEP ETU 58 Board DSMB 58 virologic failure 58 HRPC 58 q8h 58 fluorouracil 58 neratinib 58 evaluating tivozanib 58 subcutaneous injections 58 Zerenex 58 RSD# oral 58 randomized controlled clinical trials 58 pegylated interferon alfa 2b 58 NATRECOR ® 58 intravesical 58 Aflibercept 58 tolevamer 58 NATRECOR R 58 neoadjuvant chemotherapy 58 liposomal formulation 58 paclitaxel carboplatin 58 VAPRISOL 58 Alocrest 58 CLARITY study 58 Folfox 58 prospectively defined 58 clinical trials 58 Antiviral Activity 58 pharmacokinetic PK study 58 GALNS 58 azacitidine 58 interferon gamma 1b 58 estramustine 58 riociguat 58 carboplatin 58 teduglutide 58 bevacizumab 58 Tamibarotene 58 sorafenib Nexavar ® 58 intramuscular injections 58 afatinib 58 RRMS patients 58 colorectal liver metastases 58 OXi# 58 Betaferon ® 58 Cloretazine ® 58 KRN# 58 Pivotal Phase 58 voreloxin 58 biliary tract cancer 58 cediranib 58 recurrent glioblastoma multiforme 58 hypofractionated 58 recurrent malignant glioma 58 OMS# 58 veltuzumab 58 Taxotere ® 58 paclitaxel poliglumex 58 AEG# 58 huC# DM4 58 fosbretabulin 58 ACTEMRA TM 58 evaluable 58 MEND CABG II 58 NLX P# 58 IMC #B 58 Phase III Pivotal 58 tezampanel NGX# 58 melphalan prednisone 58 ixabepilone 58 CCX# B 58 Taxotere R 58 refractory multiple myeloma 58 Phase #/#a trial 58 rHuPH# 58 SCH # 58 superficial bladder cancer 58 RSD# 58 AGILECT R 58 randomized clinical trials 58 Aclidinium 58 Laquinimod 58 baminercept 58 ribavirin RBV 58 relapsed refractory 58 Ceplene/IL-2 58 subcutaneous dose 58 standard chemotherapy regimen 58 MVax 58 PRX # 58 evaluating Xcytrin 58 palifosfamide 58 peginterferon 58 JAK inhibitor 58 Perifosine 58 Elitek 58 trabedersen 58 CUSTOM III 58 ulimorelin 58 LCP AtorFen 58 plus dexamethasone 58 urate lowering 58 ritonavir boosted 58 dasatinib 58 XELOX 58 FOLOTYN 58 blinatumomab 58 VP# [004] 58 dose escalations 58 ibandronate 58 Toxicities 58 randomized trials 58 concurrent chemoradiation 58 dosing intervals 58 NXL# 57 aplindore 57 Tarceva TM 57 goserelin 57 chemotherapy regimen 57 GVAX 57 GLP toxicology studies 57 XmAb# 57 RezularTM 57 CCX# 57 blind placebo controlled 57 cetrorelix 57 ELND# 57 confirmatory Phase 57 immunomodulatory therapy 57 mcg dose 57 multicenter randomized controlled 57 teriparatide 57 angiogenesis inhibitor 57 Viramidine 57 octreotide LAR 57 achieved statistical significance 57 rNAPc2 57 relapsed SCLC 57 PMX # 57 metastatic hormone refractory 57 metastatic malignant melanoma 57 Proellex TM 57 pramlintide 57 EchoCRT 57 FAME Study 57 systemically administered 57 CIMZIA ™ 57 PSN# [002] 57 relapsed multiple myeloma 57 Torisel 57 uric acid lowering 57 methotrexate therapy 57 NGX# 57 PRIMO CABG 57 #mg BID [001] 57 tumor regression 57 ACTEMRA 57 doxorubicin cyclophosphamide 57 corticosteroid dexamethasone 57 gemcitabine Gemzar ® 57 CRx 57 SNT MC# 57 Phase III metastatic melanoma 57 Diamyd ® 57 Pralatrexate 57 preoperative chemotherapy 57 GAP #B# 57 pemetrexed 57 oral allopurinol 57 Phase 1a clinical 57 Chemophase 57 mitomycin 57 eptifibatide 57 trials RCTs 57 Mylotarg 57 Targretin 57 doxorubicin docetaxel 57 sequential dose escalation 57 GOUT 57 MGCD# [002] 57 label dose titration 57 multicenter trials 57 COPEGUS 57 TACE 57 TMC# C# 57 L MTP PE 57 Sapacitabine 57 IMA# 57 Allovectin 7 R 57 Phase III confirmatory 57 EOquin 57 HCV infected 57 lixisenatide 57 Peg IFN 57 pharmacokinetics PK 57 ASA# 57 GnRH agonist 57 PEGPH# 57 prospective randomized multicenter 57 Quinamed 57 TMC# [002] 57 Free Survival PFS 57 carfilzomib 57 Bortezomib 57 pegylated liposomal doxorubicin 57 ritonavir boosting 57 intratumoural 57 CALGB # [002] 57 PROPEL trial 57 IV bolus 57 PegIFN RBV 57 Augment Injectable 57 CHAMPION PCI 57 MAA submission 57 refractory CTCL 57 subcutaneous PRO 57 SUTENT 57 Plicera 57 PEGylated interferon beta 1a 57 randomized controlled clinical 57 Phase #b/#a clinical 57 SAR# [004] 57 TAXOTERE R 57 ANCHOR trial 57 multicenter clinical 57 initiate Phase 1b 57 ponatinib 57 ASSERT trial 57 IFN alfa 57 nimotuzumab 57 8mg/kg 57 Neuradiab 57 odanacatib 57 MBP# [001] 57 ABSORB trial 57 TTF Therapy 57 TACI Ig 57 Hepatocellular Carcinoma HCC 57 bolus injection 57 ISIS # 57 intradermal injections 57 CK # 57 #:# randomization 57 UVIDEM 57 PROSTVAC TM 57 Phase 57 androgen suppression 57 glargine 57 Tanespimycin 57 ORMD 57 PEG IFN 57 tumor resection 57 C1 INH 57 indibulin 57 analgesic efficacy 57 iniparib 57 low dose dexamethasone 57 INCB# [003] 57 DMARD 57 gemcitabine chemotherapy 57 Phase III Clinical Trial 57 PIX# [002] 57 ROCKET AF 57 metastatic HRPC 57 peginterferon alfa 2a 57 pharmacokinetic pharmacodynamic 57 bisphosphonate therapy 57 capecitabine Xeloda R 57 5 FU 57 olaparib 57 Phase IIIb study 57 HuMax CD# 57 multicenter Phase III 57 fluticasone furoate 57 phase IIb III 57 tipranavir 57 Randomized Phase II 57 antiretroviral naive 57 dual antiplatelet therapy 57 cannabinor 57 genotypic resistance 57 sorafenib 57 EndoTAG TM -1 57 Carfilzomib 57 DSMB recommended 57 SCIg 57 triple nucleoside 57 tolerability profile 57 chlorambucil 57 INTERCEPT platelets 56 lymphadenectomy 56 placebo intravenously 56 AZILECT ® 56 complete remissions 56 BENICAR HCT 56 Aptivus ® 56 hA# 56 #mg QD [002] 56 Pivotal Phase III 56 Genasense 56 BLA filing 56 sorafenib Nexavar 56 #mg QD [001] 56 Marqibo 56 Allovectin 7 56 ADAGIO study 56 Phase IIb III 56 Omacetaxine 56 BR.# 56 Asentar 56 European Sepsis Trial 56 confirmatory Phase 3 56 bortezomib Velcade 56 null responder HCV 56 EMPHASIS HF trial 56 Xcytrin 56 ZACTIMA 56 paclitaxel Taxol ® 56 visilizumab 56 abiraterone acetate 56 favorable pharmacokinetic profile 56 panitumumab 56 DermaVir Patch 56 overlapping toxicities 56 MoxDuo IR 56 dexpramipexole 56 RECIST criteria 56 Velcade bortezomib 56 clevidipine 56 alvimopan 56 Tyrima 56 GSK# [001] 56 AZILECT R 56 prucalopride 56 ISENTRESS 56 LATUDA 56 dacetuzumab 56 thymalfasin 56 O PPDS 56 APOPTONE 56 intravenously administered 56 5-FU/LV 56 Phase III clinical trials 56 interferon beta 1b 56 STRIDE PD 56 ALN VSP Phase 56 investigational monoclonal antibody 56 basal insulin 56 Urocidin 56 huN# DM1 56 L BLP# 56 TroVax ® 56 postoperative chemotherapy 56 Phenoptin 56 cART 56 tezampanel 56 pharmacokinetic profiles 56 lumiliximab 56 multicenter phase 56 PA# [002] 56 recurrent GBM 56 IIIa inhibitor 56 remission CR 56 R#/MEM # 56 L PPDS 56 RLY# 56 LB# [003] 56 tolerability profiles 56 OADs 56 pramlintide metreleptin combination 56 PREVENT IV 56 etanercept 56 Adlea 56 boosted protease inhibitor 56 assessing T DM1 56 ACTIVE W 56 antiangiogenic therapy 56 thorough QT 56 TOLAMBA 56 docetaxel Taxotere ® 56 Virulizin ® 56 histone deacetylase HDAC inhibitor 56 Initiated Phase 56 Insulin PH# 56 BRAF inhibitor 56 tremelimumab 56 coadministration 56 mRCC 56 FOSRENOL ® 56 Ophena TM 56 oral prodrug 56 plus gemcitabine 56 aflibercept VEGF Trap 56 Phase 2b kidney transplant 56 CAMMS# 56 antitumor effect 56 OPT CHF 56 cetuximab 56 MVax R 56 FORTIS M trial 56 ara C 56 LCP Tacro ™ 56 gemcitabine carboplatin 56 DASISION 56 dalbavancin 56 multicenter dose escalation 56 BrachySil TM 56 COU AA 56 enfuvirtide 56 laquinimod 56 ocrelizumab 56 certolizumab 56 GAMMAGARD LIQUID 56 pradefovir 56 RE SURGE 56 #mg dose [001] 56 KAPIDEX 56 tamoxifen therapy 56 COSIRA trial 56 RE LY ® 56 DCVax ® Brain 56 ofatumumab HuMax CD# 56 DOXIL 56 topotecan 56 ACAPODENE 56 PROSTVAC ® 56 dabigatran etexilate 56 ERBITUX 56 lenalidomide Revlimid R 56 lopinavir r 56 Revlimid lenalidomide 56 VITAL Trial 56 AZOR 56 liposomal doxorubicin 56 pivotal bioequivalence 56 pyridostigmine 56 F FDG PET 56 tivozanib 56 trastuzumab DM1 56 certolizumab pegol 56 multicenter prospective 56 oral diclofenac 56 PD LID 56 NVA# 56 Pemetrexed 56 ENDEAVOR II 56 factorial design 56 lubiprostone 56 lipid lowering therapy 56 Tolvaptan 56 receptor tyrosine kinase inhibitor 56 Viprinex 56 Dasatinib 56 daclizumab 56 Spheramine 56 q#d 56 eltrombopag 56 NEUPOGEN 56 pegylated interferon alfa 2a 56 inhibitor RG# 56 remission induction 56 recurrent metastatic 56 EURIDIS 56 Phase III VISTA 56 NCCTG N# 56 subcutaneously administered 56 indolent NHL 56 mTOR inhibition 56 VFEND 56 liver metastases 56 USL# 56 Pharmacokinetics PK 56 FTY# 56 tacrolimus ointment 56 Ophena 56 #I TM# 56 Pharmacokinetic 56 CR nPR 56 Study GL# 56 ataluren 56 pegloticase 56 TRISENOX 56 locoregional recurrence 56 Pegasys plus Copegus 56 CANCIDAS 56 fallopian tube cancers 56 pegylated interferon 56 Triapine R 56 abciximab 56 ExTRACT TIMI 56 farletuzumab 56 Alpharadin 56 OMP #M# 56 tgAAC# 56 subcutaneous dosing 56 CEQ# 56 IRX 2 56 cabazitaxel 56 MEND CABG 56 tacrolimus 56 generation purine nucleoside 56 milatuzumab 56 CBLC# 56 gout flares 56 AVE# 56 nucleoside analog 56 lenalidomide dexamethasone 56 TASQ 56 label multicenter randomized 56 OHR/AVR# 56 peginesatide 56 Xanafide 56 ocular hypertension 56 Aplidin 56 SVR# 56 Symadex 56 Alzhemed TM 56 octreotide implant 56 lintuzumab SGN 56 chemotherapy FOLFOX 56 pharmacokinetic parameters 56 Altastaph 56 fluoropyrimidine 56 TOCOSOL Paclitaxel 56 sipuleucel T 56 cinacalcet 56 refractory acute myeloid 56 eprotirome 56 PDX pralatrexate 56 NCCTG 55 adjuvant radiation 55 mg/m2 administered 55 pegfilgrastim 55 mycophenolate mofetil 55 QUADRAMET 55 sustained virologic response 55 PROCHYMAL 55 BCX# 55 alkylating agent 55 REG2 55 AIR CF1 55 Decitabine 55 subcutaneous formulation 55 safety tolerability 55 SABCS 55 zonisamide SR 55 INCB# [002] 55 LPV r 55 Doxil ® 55 Triapine 55 CIMZIA TM certolizumab pegol 55 symptomatic BPH